Eisai To Manufacture Breast Cancer Drug In Europe
This article was originally published in PharmAsia News
Executive Summary
Eisai announced June 26 a ¥5 billion additional investment to European Knowledge Center in Hatfield, a suburb of London. The company completed and opened the facility the same day. Eisai plans to manufacture breast cancer drug E7389 starting in 2011. Currently under Phase II trials in Japan and Phase III trials in the U.S. and Europe, Eisai aims for a 2010 NDA submission. Eisai previously invested ¥160 million to the center; the production line has an annual capacity of 400 million tablets. Positioned as a global strategic product for Eisai, E7389 is estimated to become a ¥100 billion blockbuster drug. (Click here for more - Japanese language